Qiagen


Strong Q2; Thermo Fisher’s tender offer ends on 10 August

05/08/20 -"Sales momentum accelerated in Q2 20, benefiting from robust demand for COVID-19 solutions. Q3 is expected to be strong and, given the improved business dynamics, Thermo Fisher increased the takeover ..."

Pages
62
Language
English
Published on
05/08/20
You may also be interested by these reports :
19/04/24
EssilorLuxottica’s Q1 sales performance was slightly ahead of the market’s expectations. Group revenue grew by 5.5% yoy (+65bp vs the consensus), led ...

19/04/24
Orpea’s 2023 key underlying results met the guidance. The management noted the inflationary staff costs and yet-to-restore occupancy which weighed ...

18/04/24
While the near-term performance is expected to be impacted by various challenges, there are still some promising takeaways from our recent discussion ...

16/04/24
Drägerwerk reported softer-than-expected Q1 24 numbers, with sales declining by 2.6%. As expected, growth in the safety segment partly offset the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO